

Mayo Clinic and ASU Alliance for Health Care Accelerator

Category:

Best Incubator, Accelerator, Equity

Program/Fund Name:

MAYO CLINIC AND ARIZONA STATE U. ALLIANCE for HEALTH CARE ACCELERATOR

Corporate Name:

Mayo Clinic and Arizona State University

Date of Creation:

2017-12-31

Indications:

The Mayo Clinic and Arizona State University Alliance for Health Care Accelerator is designed to advance solutions that directly address high-priority clinical needs and reduce gaps in care. Each cohort company is selected for its potential to significantly impact patient outcomes across a spectrum of medical and operational domains.

Each company is selected based on alignment with unmet needs identified by Mayo Clinic and Arizona State University scientists and clinical leaders, translational readiness, and capacity to scale within complex health systems. The accelerator's emphasis on impact, equity, and clinical relevance ensures that participating companies are not only advancing science but reshaping the future of care by bringing the best products to patients, products that serve to improve the human condition.

Therapeutic Areas:

Our cohort companies represent a broad spectrum of technologies spanning artificial intelligence, medical devices, diagnostics, biologics, and digital health. We empower startups tackling challenges across the breadth of healthcare verticals, including but not limited to:

- Chronic Care & Aging:
MiiCare uses conversational AI and remote monitoring to support aging-in-place and chronic disease management in vulnerable populations.
- Clinical Workflow & Patient Communication:

MiiHealth integrates generative AI into clinical settings to streamline provider documentation, improve patient communication, and enable specialty-specific triage.

- Access & Global Primary Care:

Zuri Health delivers affordable, accessible care across Africa through SMS- and app-based platforms, bridging the last-mile in health access.

- Brain Health & Rehabilitation:

HealthTech Connex pioneers neuro-diagnostics and recovery tools for concussion and brain performance optimization.

- Orthopedics & Regenerative Medicine:

Abanza develops next-gen orthopedic implants that promote natural healing, reduce surgical complexity, and improve outcomes.

- Male Fertility & Reproductive Health:

Paterna addresses male infertility with novel diagnostics and digital tools for reproductive health and wellness.

- Advance Diagnostic:

TOBY and Pharos Diagnostics creates specialized advanced cancer diagnostics

- Health Equity Enablement:

TruLite Health empowers health systems with digital tools and analytics to operationalize health equity across clinical workflows and population health.

- Biologics & Specialty Therapeutics:

Apex Biologix is advancing biologic platforms to treat complex diseases, with scalable production for widespread clinical adoption.

We are proud to support a new generation of MedTech, Biotech and Life Science companies not just accelerating products, but reimagining the future of healthcare.

FUND & SERVICE File Document upload:

[**Golden Book Corp ad mock up_Healthcare_JH.pptx**](#)

[**100 word pitch_Healthcare_JH.docx**](#)

[**Accelerator_Promo_Source.mp4**](#)

History of the development of the fund / Incubators:

Launched in 2017 and re-imagined in 2019, the Mayo Clinic and Arizona State University (ASU) Alliance for Health Care Accelerator was created through a unique partnership between two globally recognized leaders in healthcare and innovation. The program was initially built to support early-stage medical technology and subsequently biotech and life science companies with high potential to transform clinical practice, improve patient outcomes, and bring breakthrough solutions to market faster.

Recognizing the critical need to bridge the gap between healthcare innovation and clinical validation, Mayo Clinic and ASU developed a selective, outcomes-focused accelerator model. By combining Mayo Clinic's deep clinical expertise with ASU's

entrepreneurial and translational research strengths, the program offers an unparalleled platform for startups seeking to test, refine, and validate their technologies in real-world healthcare settings.

Headquartered in Phoenix, Arizona a fast-growing hub for biosciences and health innovation, the accelerator was intentionally placed at the intersection of clinical excellence and academic entrepreneurship. It serves as a gateway to Mayo Clinic's clinical environment and ASU's expansive innovation ecosystem, giving startups access to expert mentorship, end user feedback, and business strategy support.

Each year, companies from across the globe apply to participate in the program. Every continent, but for Antarctica, has been represented. Selected ventures benefit from direct interactions with Mayo Clinic clinicians and researchers, customized support from ASU faculty, and curated sessions with investors, regulatory experts, and health system executives. The focus is on helping companies refine their value proposition, validate their technology, and accelerate toward meaningful commercialization milestones.

Since its inception, the Accelerator has supported more than 50 companies in areas such as diagnostics, remote monitoring, surgical technologies, AI-enabled solutions, and digital health. Several participants have gone on to secure venture funding, regulatory approvals, and clinical collaborations with Mayo Clinic and other leading institutions. These outcomes underscore the program's ability to de-risk early-stage innovation while amplifying its potential for real world impact.

Beyond startup development, the Health Care Accelerator is a cornerstone of the broader vision for Discovery Oasis an emerging biomedical innovation district adjacent to Mayo Clinic's Phoenix campus. The program plays a foundational role in building a vibrant ecosystem where clinicians, researchers, entrepreneurs, and industry partners converge to solve some of healthcare's most pressing challenges.

By aligning the strengths of clinical practice, academic research, and entrepreneurship, the Mayo Clinic and ASU Alliance for Health Care Accelerator is redefining how breakthrough health technologies are developed and deployed. It stands as a global model for how cross-sector collaboration can drive scalable innovation and accelerate the path from idea to impact.

History of the development of the fund / Incubators:

N/A

HISTORY & FOCUS File Document upload:

N/A

How do you address your portfolio needs:

The Mayo Clinic and ASU Alliance for Health Care Accelerator is dedicated to nurturing the next generation of healthcare innovations by providing tailored support to early-stage companies that are advancing life changing healthcare solutions. Through our comprehensive approach, we address the diverse needs of our portfolio companies, ensuring they have the resources, mentorship, and access to networks necessary to succeed in the highly complex and competitive healthcare landscape.

1. Access to Expertise and Resources

Our program is uniquely positioned to offer portfolio companies access to the unparalleled medical expertise of Mayo Clinic, one of the world's leading healthcare organizations. Companies receive mentorship from top tier clinicians, researchers, and innovators who are at the forefront of medical advancements. This partnership allows companies to align their products with real world clinical needs, ensuring their solutions address pressing healthcare challenges. Furthermore, through ASU's cutting-edge research and technology capabilities, we provide access to a wealth of academic resources, enabling our portfolio to leverage the latest scientific breakthroughs in product development.

2. Regulatory and Market Guidance

Navigating regulatory pathways and market adoption are critical hurdles for healthcare startups. Our Accelerator offers tailored regulatory support, providing guidance through the FDA approval process and navigating complex regulatory requirements in both the U.S. and global markets. This expertise helps streamline the journey from product concept to market ready solution. Additionally, our program helps startups assess market viability, identify key stakeholders, and establish strategic partnerships with payers, providers, and healthcare systems to drive adoption.

3. Customized Business Development Support

Recognizing that every healthcare startup has unique needs, we offer personalized business development support. This includes assistance with go-to-market strategies, pricing, reimbursement, and scaling operations. We work closely with our portfolio companies to refine their business models and prepare them for investment opportunities, ensuring they are well positioned for growth and long term sustainability. Our team also facilitates introductions to potential investors, strategic partners, and industry leaders who can drive critical milestones for product development and commercialization.

4. Collaborative Ecosystem

Our Health Care Accelerator fosters a collaborative environment where startups can engage with like minded innovators, industry experts, and researchers. This community of entrepreneurs, clinicians, and technologists enables portfolio companies to exchange knowledge, share challenges, and co-develop solutions that can have a transformative

impact on healthcare. Through regular networking events, workshops, and innovation challenges, we promote cross-disciplinary collaboration that accelerates problem solving and product innovation.

5. Post Accelerator Success

The support doesn't end once companies graduate from the Health Care Accelerator program. We provide ongoing resources to ensure long-term success, including continued access to Mayo Clinic and ASU networks, mentorship, and opportunities for funding and partnership. This enduring relationship helps our portfolio companies thrive, contributing to sustained innovation in the MedTech space.

By addressing the multifaceted needs of our portfolio companies, the Mayo Clinic and ASU Alliance for Health Care Accelerator plays a pivotal role in advancing healthcare innovation, translating groundbreaking ideas into solutions that improve patient care and outcomes globally.

Impact / Metrics to measure Success:

The Mayo Clinic and Arizona State University Alliance for Health Care Accelerator is distinguished by its outcomes-driven model, designed to de-risk early stage technologies and accelerate their path to market adoption and patient impact. Our success is measured not only by the advancement of participating companies but also by their ability to integrate into complex health care systems and deliver solutions that improve clinical outcomes, reduce cost of care, and enhance patient experiences.

Company Advancement & Capital Formation: Since its inception, the Accelerator has supported over 50 health care startups from across the globe, with more than 70% successfully raising follow-on funding within 12-18 months of completion. Collectively, participating companies have secured over \$350M in venture capital, non-dilutive grants, and strategic partnerships.

Clinical Validation & Commercial Pilots: A key differentiator of the Accelerator is the facilitation of clinical collaborations with Mayo Clinic subject matter experts and access to Mayo Clinic's integrated clinical environment. Over 60% of alumni companies have initiated pilot programs or clinical validation studies with Mayo Clinic or ASU, accelerating their regulatory and commercialization timelines.

Strategic Partnerships & Acquisitions: Several Accelerator alumni have secured strategic partnerships and notably four companies have been acquired by major healthcare players reflecting strong external validation of our vetting and acceleration model.

Mentorship & Ecosystem Impact: Each startup benefits from curated mentorship by

Mayo Clinic and ASU faculty, seasoned entrepreneurs, and industry veterans. To date, over 60 clinical and academic experts have served as mentors. In addition, the Accelerator catalyzes local and national economic growth by attracting startups to Arizona's emerging health innovation corridor, strengthening the regional biotech, life science and medtech ecosystem.

Our impact is best reflected in the patient-centric technologies that have advanced toward real-world use. Whether it's AI-driven diagnostics, novel surgical robotics, or wearable monitoring platforms, our Accelerator is a launchpad for transformational healthcare solutions. The collective success of our companies and the lives improved by their innovations represents our most meaningful measure of impact.

Why your model is innovative, and/or how it will improve the human condition:

The Mayo Clinic and Arizona State University (ASU) Alliance for Health Care Accelerator is a uniquely integrated platform designed to propel early-stage healthcare companies into clinical and commercial success. At the intersection of world-class clinical expertise and research leadership from Mayo Clinic and the innovation, engineering, and entrepreneurship strength of ASU, our accelerator bridges a critical gap in the health innovation ecosystem.

What makes our program truly innovative is its direct alignment with real world clinical needs, access to decision making clinicians, and personalized navigation of complex health system pathways. We don't just teach companies how to commercialize, we actively co-develop their path to patient impact. Participants receive tailored mentorship from leading physicians, scientists, and regulatory experts, and gain access to one of the most trusted and respected healthcare brands in the world.

Our dual institution approach enables participants to benefit from ASU's strength in translational research, bioengineering, and venture creation while simultaneously leveraging Mayo Clinic's deep clinical validation, trial infrastructure, and integration into patient care. This allows companies to iterate not just on the bench, but at the bedside accelerating both technical and clinical readiness.

Beyond innovation, our mission is fundamentally human-centered. The program is designed to improve the human condition by bringing lifesaving and life enhancing technologies to patients faster, smarter, and more effectively. Whether it's AI enabled diagnostic tools, next generation wearables, or novel therapeutic platforms, the companies we support are working on breakthrough solutions that have the potential to transform healthcare delivery and outcomes across the globe.

Importantly, we are intentional about supporting technologies that address health

disparities, improve access, and reduce costs. Many of our alumni companies focus on conditions that are underserved or disproportionately affect vulnerable populations. Our model emphasizes not only innovation, but also health equity and systemic transformation.

The Mayo Clinic and ASU Alliance for Health Care Accelerator has helped dozens of high impact startups, secured significant follow-on funding, and fostered collaborative ventures between academia, health systems, and industry. But more than metrics, we measure our success by the lives changed through the innovations we help bring to the world.

This is not just an accelerator. It is a convergence engine where breakthrough ideas meet clinical insight and compassionate purpose to shape the future of medicine.

Please provide appropriate references (PubMed, Abstract, Website):

Mayo Clinic and ASU MedTech Accelerator

Website: <https://medtechaccel.com>

Description: A flagship collaboration between Mayo Clinic and Arizona State University to identify, accelerate, and scale innovative healthcare technologies. The accelerator provides early-stage healthcare companies with clinical and commercial validation through direct engagement with Mayo Clinic experts and ASU's robust innovation ecosystem.

The site provides more details into the program, list the past participants each with a short video (note, the 2025 cohort videos have been shot and are in final production). There is as well, a list of new articles under the \"about tab-press\".

Listed are a few selected references from some of our portfolio companies

Vinzani, M., Alshareef, M., & Eskandari, R. (2023). Use of a prophylactic retrograde-flushing device in high-risk pediatric patients with ventriculoperitoneal shunts: A technical note. *Pediatric Neurosurgery*, 58(3), 136
141pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov.
<https://doi.org/10.1159/000530869> (Anuncia)

Dixon, P. C., Dubeau, S., Roy, J.-F., & Fournier, P.-A. (2025). Automatic cough detection via a multi-sensor smart garment using machine learning. *Computers in Biology and Medicine*, 191, 110192 pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov.
<https://doi.org/10.1016/j.compbiomed.2025.110192> (Hexoskin)

Cairns, A., & Bogan, R. (2019). The SinuSonic: Reducing nasal congestion with acoustic

vibration and oscillating expiratory pressure. *Medical Devices: Evidence and Research*, 12, 305-310 [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov)[pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov).
<https://doi.org/10.2147/MDER.S212207> (SinuSonic)

Soler, Z. M., Nguyen, S. A., Salvador, C., Lackland, T., Desiato, V. M., Storck, K., & Schlosser, R. J. (2020). A novel device combining acoustic vibration with oscillating expiratory pressure for the treatment of nasal congestion. *International Forum of Allergy & Rhinology*, 10(5), 610-618 [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov)[pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov).
<https://doi.org/10.1002/alr.22537> (SinuSonic)

Rim, T. H., Lee, C. J., Tham, Y.-C., Cheung, N., Yu, M., Lee, G., Kim, Y., ... Wong, T. Y. (2021). Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs. *The Lancet Digital Health*, 3(5), e306-e316 [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov). [https://doi.org/10.1016/S2589-7500\(21\)00043-1](https://doi.org/10.1016/S2589-7500(21)00043-1) (Mediwhale)

Peng, Q., Rim, T. H., Soh, Z. D., Chee, M. L., Tham, Y.-C., Zhu, Z., ... Cheng, C.-Y. (2025). Predictive potential of retina-based biological age in assessing chronic obstructive pulmonary disease risk. *Clinical & Experimental Ophthalmology*, 51(2), Advance online publication mediwhale.com. <https://doi.org/10.1111/ceo.14501> (Mediwhale)

Chiu, T.-L., Lin, S.-Z., Ahmed, T., Huang, C.-Y., & Chen, C.-H. (2022). Pilot study of a new type of machine vision-assisted stereotactic neurosurgery for EVD placement. *Acta Neurochirurgica*, 164(9), 2385-2393 [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov)[pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov).
<https://doi.org/10.1007/s00701-022-05287-7> (Brain Navi)

Pacilè, S., Lopez, J., Chone, P., Bertinotti, T., Grouin, J. M., & Fillard, P. (2020). Improving breast cancer detection accuracy of mammography with the concurrent use of an artificial intelligence tool. *Radiology: Artificial Intelligence*, 2(6), e190208 [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov)[pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/pubmed.ncbi.nlm.nih.gov).
<https://doi.org/10.1148/ryai.2020190208> (Therapixel)